Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 (NCT07486934)

🧪 Interventions in This Study

• zeleciment basivarsen (DYNE-101) (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (34 Sites)

Showing the first 25 of 34 sites.

• UCSD - Altman Clinical and Translational Research Institute — La Jolla, California
• UCLA Medical Center (Department of Neurology) — Los Angeles, California
• Rare Disease Research, LLC — Atlanta, Georgia
• IU Health Neuroscience Center — Indianapolis, Indiana
• Roy Blunt NextGen Precision Health Institute — Columbia, Missouri
• Rare Disease Research, LLC — Hillsborough, North Carolina
• The University of Texas Health Science Center at San Antonio — San Antonio, Texas
• University of Utah Clinical Neurosciences Center — Salt Lake City, Utah
• Virginia Commonwealth University - Biotech One — Richmond, Virginia
• UZA — Edegem,
• UZ Leuven — Leuven,
• Rigshospitalet, (Neuromuscular Clinic and Research Unit, Department 8077) — Copenhagen,
• AP-HP, Hôpital Raymond-Poincaré — Garches,
• CHU Marseille - Hôpital de la Timone (APHM) — Marseille,
• CHU de Nantes - Hôtel-Dieu — Nantes,
• Pitié-Salpêtrière Hospital — Paris,
• CHU de Toulouse - Hôpital Pierre-Paul Riquet — Toulouse,
• LMU Klinikum der Universität München Neurologische Klinik und Poliklinik Friedrich-Baur-Institut Campus Innenstadt — Munich, Bavaria
• Universitätsklinikum Bonn AöR Zentrum für Neurologie Klinik für Neuroimmunologie und Neuromuskuläre Erkrankungen — Bonn, North Rhine-Westphalia
• Charité Universitätsmedizin Berlin Campus-Buch Muscle Research Unit — Berlin, State of Berlin
• Centro Clinico Nemo Brescia, Fondazione Serena ETS — Gussago, Brescia
• Centro Clinico Nemo Milano, Fondazione Serena ETS — Milan, Milano
• Fondazione Policlinico Universitario A. Gemelli IRCCS - Department of Women's, Child and Public Health Sciences - UOC Neuropsichiatria Infantile — Roma, Roma
• Azienda Ospedaliero-Universitaria Sant'Andrea - UOC Neurologia — Roma, Roma
• Niigata National Hospital, National Hospital Organization — Kashiwazaki, Niigata

📞 Contact the Study Coordinator

Phone: (781) 317-1919

Email: clinicaltrials@dyne-tx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myotonic Dystrophy Type 1 (DM1)

• A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy — Jonquière, Quebec
• A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) — San Carlos, California
• Remote Assessments and Genetic Determinants of Myotonic Dystrophy — Rochester, New York
• Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 — Stanford, California

Explore by condition: All Myotonic Dystrophy Type 1 (DM1) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.